# The Shift Toward Non-Animal Biomedical Research Methodologies Regulatory changes and advanced organ-on-a-chip technologies are finally challenging traditional animal testing models. - **Source:** [Hacker News (news.ycombinator.com)](https://brifing.si/source/13c923cd-6d99-442b-9b8b-1181f4d8cd91) - **Published:** 2026-10-19 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/06fbf7f6-ac28-42ed-b23d-c48f71b9ff18 ## The Evolution of Lung Models Seventeen years ago, Donald Ingber at Harvard’s Wyss Institute introduced a lung-on-a-chip model. This device, smaller than a USB stick, used polymer channels to simulate human breathing mechanics. Unlike static tissue cultures, this system successfully replicated inflammatory responses, providing a critical proof-of-principle for replacing traditional animal models in pharmaceutical research. ## Regulatory Shifts at the FDA The FDA Modernization Act 2.0, passed in late 2022, marked a turning point by authorizing non-animal methods for preclinical drug studies. By September 2026, the agency moved to replace the term animal tests with nonclinical tests in regulations. This change officially validates human-cell systems and computer models as acceptable research standards. ## The Failure of Animal Surrogates Approximately 92 percent of drugs entering U.S. clinical trials fail to reach the market. These failures often stem from animal models failing to predict human safety or efficacy accurately. Diseases of the brain, heart, and cancer show particularly high attrition rates, suggesting that animals are often poor surrogates for complex human physiology. ## Advancements in Organ-on-a-Chip Modern technologies have expanded beyond lungs to include brains, hearts, kidneys, and placentas on a chip. Researchers can now link up to ten organs together to simulate multi-organ human physiology. These systems are further supported by artificial intelligence tools that analyze generated data to optimize future experiments in an iterative loop. ## Commercialization and Standardization Challenges Academic prototypes must transition into mass-produced commercial products to gain regulatory trust. Ingber notes that even minor variations in hydrogel scaffolds can significantly alter growth patterns. Achieving global consistency requires rigorous standardization of workflows, ensuring that the same results can be replicated in any laboratory environment across the world. ## Change Management Over Technology Thomas Hartung of Johns Hopkins University emphasizes that the transition is primarily a change management challenge rather than a purely technical one. Moving away from established animal-based research requires deep shifts in policy, professional training, and institutional culture. Scientists must now learn to integrate in vitro models alongside their traditional animal-based research. ## Industry Adoption and Pressure Pharmaceutical companies are increasingly seeking alternatives after facing regulatory pushback. Ilka Maschmeyer of TissUse reports that firms are now approaching biotech companies for organ-on-a-chip data after the FDA rejected animal-only submissions. This trend indicates that regulatory pressure is forcing a shift in how major pharmaceutical players approach their drug development pipelines. ## Global Policy Alignment Beyond the United States, the European Commission and the United Kingdom have announced plans to phase out animal testing. The OECD has also updated its influential guidelines to support the expanded use of new approach methodologies. These international efforts create a unified global framework that incentivizes researchers to adopt non-animal testing protocols. ## NIH Funding Requirements In 2025, the National Institutes of Health mandated that grant applicants using animal models must also incorporate non-animal research. This policy change forces researchers to utilize real-world data or NAMs alongside traditional methods. By tying funding to these requirements, the NIH is actively accelerating the integration of modern, non-animal testing technologies. ## The Complexity of Validation Validating new approach methodologies involves conducting head-to-head comparisons with established animal experiments. This process is essential to prove that these systems are reliable and trustworthy. However, simply outperforming animal models is not enough; the systems must meet fine performance criteria to be accepted as a standard for human safety and efficacy. ## The Future of Toxicology As NAMs become more sophisticated, the focus shifts toward practical implementation. The goal is to make animal studies the exception rather than the norm in drug safety testing. While the transition is complex, the combination of regulatory mandates and improved technological capabilities suggests a fundamental shift in the future of biomedical research. ## A New Research Paradigm The shift toward non-animal testing represents a landmark change in scientific methodology. By moving away from flawed animal surrogates, researchers aim to improve the success rates of new drug development. The integration of organ-on-a-chip systems and AI-driven analysis marks the beginning of a more accurate, human-centric era in modern biomedical engineering. ## Sources covering this story - https://spectrum.ieee.org/alternatives-to-animal-testing — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._